In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms

被引:64
作者
Dawis, MA
Isenberg, HD
France, KA
Jenkins, SG
机构
[1] Dr Betsy Herold, CUNY Mt Sinai Sch Med, Div Pediat Infect Dis, New York, NY 10029 USA
[2] CUNY Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA
[3] CUNY Mt Sinai Sch Med, Ctr Clin Labs, New York, NY 10029 USA
关键词
synergy; fluoroquinolones; gatifloxacin; susceptibility testing;
D O I
10.1093/jac/dkg238
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To study the in vitro interaction of gatifloxacin in combination with gentamicin and with the beta-lactams cefepime, meropenem and piperacillin against clinical isolates of Stenotrophomonas maltophilia, Pseudomonas aeruginosa, Burkholderia cepacia, extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae, vancomycin-resistant Enterococcus faecium(VRE) and methicillin-resistant Staphylococcus aureus(MRSA). Methods: The activity of each drug alone was determined by an agar dilution method. Chequer-board synergy testing was then performed against all the isolates. Time-kill assays were done on selected isolates to assess correlation with the chequerboard results. Results: Synergy was demonstrated with the following combinations at achievable serum concentrations: gatifloxacin/piperacillin for 80% and gatifloxacin/cefepime for 60% of S. maltophilia; gatifloxacin/gentamicin for 60%, and gatifloxacin/cefepime for 50% of ESBL-producing K. pneumoniae, and in all drug combinations for 50-70% of P. aeruginosa. Indifference was noted for the majority of B. cepacia and VRE isolates. Antagonism at therapeutic serum levels was observed with gatifloxacin/piperacillin against a single isolate of B. cepacia. No distinct trend in drug interaction was seen with the different drug combinations against MRSA. Time-kill analyses against selected isolates confirmed the synergic activity of the following drug combinations seen in the chequerboard assays: gatifloxacin/cefepime and gatifloxacin/ piperacillin against P. aeruginosa, gatifloxacin/gentamicin against B. cepacia, and gatifloxacin/ gentamicin and gatifloxacin/meropenem against ESBL-producing K. pneumoniae. Conclusions: Gatifloxacin was synergic with the beta-lactams piperacillin, cefepime and meropenem, and with gentamicin against some drug-resistant pathogens. Some of the time-kill analyses against P. aeruginosa, B. cepacia and ESBL-producing K. pneumoniae were in accordance with chequerboard results. Time-kill analyses against S. maltophilia did not confirm the synergy seen in chequerboard testing.
引用
收藏
页码:1203 / 1211
页数:9
相关论文
共 26 条
[1]   Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E test methods [J].
Biedenbach, DJ ;
Croco, MAT ;
Barrett, TJ ;
Jones, RN .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1999, 18 (06) :428-431
[2]   Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms [J].
Blondeau, JM ;
Laskowski, R ;
Bjarnason, J ;
Stewart, C .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 14 (01) :45-50
[3]  
ELIOPOULOS G M, 1988, Clinical Microbiology Reviews, V1, P139
[4]   Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs [J].
Fish, DN ;
Choi, MK ;
Jung, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (06) :1045-1049
[5]   In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin [J].
Fung-Tomc, J ;
Minassian, B ;
Kolek, B ;
Washo, T ;
Huczko, E ;
Bonner, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (04) :437-446
[6]   Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients:: Geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999) [J].
Gales, AC ;
Jones, RN ;
Forward, KR ;
Liñares, J ;
Sader, HS ;
Verhoef, J .
CLINICAL INFECTIOUS DISEASES, 2001, 32 :S104-S113
[7]  
Gerberding J, 1999, AM J INFECT CONTROL, V27, P520
[8]   Synergistic activities of gatifloxacin in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species [J].
Gradelski, E ;
Valera, L ;
Bonner, D ;
Fung-Tomc, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (11) :3220-3222
[9]   Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents [J].
Gradelski, E ;
Kolek, B ;
Bonner, DP ;
Valera, L ;
Minassian, B ;
Fung-Tomc, J .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 17 (02) :103-107
[10]   Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997-1998 [J].
Huczko, E ;
Conetta, B ;
Bonner, D ;
Valera, L ;
Stickle, T ;
Macko, A ;
Fung-Tomc, J .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 16 (04) :401-405